At MannKind Corporation (NASDAQ: MNKD), we focus on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.

Our focus is patients, our passion is innovation.

Our Journey

Over twenty-five years ago, in February 1991, the company – now known as MannKind Corporation—was founded. Originally incorporated as Pharmaceutical Discovery Corporation (PDC) in Elmsford, New York, it developed its Technosphere® technology, a versatile drug delivery platform that allows the pulmonary administration of therapeutics currently requiring administration by injection, shortly after its formation.

In the mid-1990s, Alfred Mann – at the time, CEO of MiniMed Inc. – started working with PDC through a collaborative research effort and eventually became a significant shareholder. 

In 2001, the company merged with two other companies owned by Alfred Mann (CTL Immunotherapies Corp. and Allecure Corp.) and the surviving company changed its name to MannKind Corporation.  As a result of this merger, we relocated the corporate headquarters to Valencia, California while focusing the East coast operations – by this time, located in Danbury, Connecticut – on improving the Technosphere® technology and developing our innovative line of delivery devices. 

In 2014, our first product Afrezza® (insulin human) inhalation powder, which we manufactured in our state-of-the art manufacturing facility in Danbury, Connecticut, was approved by the FDA and launched soon after. We are currently commercializing Afrezza, the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

Today, MannKind Corporation is headquartered in Westlake Village, California. The East coast operations reside in Danbury, Connecticut, and our field sales and field medical employees are dispersed across the United States to best serve our customers.